Drug safety special: chasing shadows.
Frantz
Simon
S
D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards* / Q000639:trends; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects; D016208:Databases, Factual / Q000639:trends; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D006279:Health Maintenance Organizations; D006323:Heart Arrest / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D007783:Lactones / Q000009:adverse effects; D007880:Legislation, Drug; D008297:Male; D012189:Retrospective Studies; D018570:Risk Assessment / Q000191:economics; D012449:Safety / Q000331:legislation & jurisprudence / Q000592:standards / Q000706:statistics & numerical data; D013450:Sulfones / Q000009:adverse effects; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence / Q000592:standards
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib